Instem provides advanced and best-in-class IT solutions to the global health and life sciences community which improves the productivity of their processes in the discovery and development of new drugs, therapies and products.

Founded in the United Kingdom in 1969, Instem has deep roots internationally across North America, EMEA and APAC. We maintain a commercial and technical presence throughout these regions and pride ourselves on localized support for our diverse client base.

BRIC-inStem At the forefront of research and innovation in stem cell science and regenerative medicine. Focused on developing indigenous solutions for societal benefit.

Instem is a leading supplier of SaaS platforms across Discovery, Study Management, Regulatory Submission and Clinical Trial Analytics.

Instem | 12,394 followers on LinkedIn. SaaS Products & Services for R&D that drive discovery, accelerate studies, and advance your research.

Founded in 1969 and headquartered in Staffordshire, England, Instem has grown organically and via acquisition into one of the world’s leading developer of software and technology-enabled services for the acceleration and streamlining of drug discovery & development.

2023年8月30日 · Shares in Instem Plc soared over 39% on Wednesday after the British life sciences software company agreed to a take-private deal with French private equity firm Archimed SAS for 203 million...

2021年3月22日 · Across the entire drug development value chain, every day Instem solutions are meeting the rapidly expanding needs of life science organizations for data-driven decision making, leading to safer, more effective products.

2023年11月27日 · Now, as part of ARCHIMED, Instem sees exceptional opportunity to increase the power of current and future in silico modelling and prediction projects, leveraging its new technology and data ...

Instem’s leadership team is dedicated to advancing life sciences R&D with cutting-edge SaaS platforms that drive discovery, streamline study management, and accelerate the journey from research to regulatory submission.